Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Hofstra University · Northwell Health · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
465
total citations
- FWCI
- 35.09
- Percentile
- 100%
- References
- 45
Citations per year
Authors
13- RFRichard FurieCorresponding
Hofstra University, Northwell Health
- EFEric F. Morand
Monash University
- INIan N Bruce
Versus Arthritis, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre
- SMSusan Manzi
Allegheny Health Network
- KKKenneth Kalunian
University of California, San Diego
Topics & keywords
Topics
Keywords
- Medicine
- Azathioprine
- Prednisone
- Internal medicine
- Placebo
- Mycophenolic acid
- Lupus erythematosus
- Gastroenterology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.